Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 05/01/2026 | CALL | $55.00 | 10,995 | +10,093 | +1,118.96% |
| 05/15/2026 | PUT | $37.00 | 4,379 | +3,115 | +246.44% |
| 09/18/2026 | CALL | $50.00 | 2,803 | +1,977 | +239.35% |
| 05/15/2026 | CALL | $50.00 | 25,916 | +1,915 | +7.98% |
| 05/01/2026 | PUT | $30.00 | 1,686 | +1,682 | +42,050.00% |
| 05/01/2026 | PUT | $39.00 | 1,576 | +1,523 | +2,873.58% |
| 05/01/2026 | CALL | $60.00 | 916 | -104 | -10.20% |
| 06/18/2026 | PUT | $22.50 | 2,301 | -124 | -5.11% |
| 05/15/2026 | CALL | $26.00 | 451 | -136 | -23.17% |
| 05/15/2026 | PUT | $30.00 | 1,655 | -316 | -16.03% |
| 06/18/2026 | CALL | $50.00 | 1,996 | -565 | -22.06% |
| 06/18/2026 | PUT | $20.00 | 10,535 | -2,196 | -17.25% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 9.96M | 1.37B |
| Vanguard International Growth Fund | 2.49% | 9.9M | 1.36B |
| Vanguard 500 Index Fund | 1.93% | 7.66M | 1.05B |
| Invesco ETF Tr-Invesco NASDAQ 100 ETF | 1.47% | 5.83M | 803.49M |
| Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.45% | 5.78M | 796.35M |
| SPDR S&P 500 ETF Trust | 0.93% | 3.71M | 511.13M |
| Fidelity 500 Index Fund | 0.92% | 3.67M | 505.99M |
| iShares Core S&P 500 ETF | 0.77% | 3.06M | 420.95M |
| Vanguard U.S. Growth Fund | 0.74% | 2.93M | 403.55M |
| Select Sector SPDR Fund-Health Care | 0.70% | 2.77M | 382.16M |
| Vanguard Growth Index Fund | 0.69% | 2.73M | 375.5M |
| iShares NASDAQ Biotechnology ETF | 0.68% | 2.72M | 374.27M |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.64% | 2.56M | 353.12M |
| Vanguard Specialized-Health Care Fund | 0.57% | 2.25M | 309.92M |
| Price (T.Rowe) Health Sciences Fund | 0.30% | 1.19M | 163.53M |
| Growth Fund Of America Inc | 0.28% | 1.12M | 154.54M |
| American Funds Insurance Ser-Growth Fund | 0.19% | 750k | 103.31M |
| Fidelity Growth Company Fund | 0.17% | 668.97k | 92.14M |
| Schwab Capital Trust-Schwab S&P 500 Index Fund | 0.16% | 639.04k | 88.02M |
Moderna's Legal Hit Steals Spotlight From Strong Sales
05/01 10:44 am
Benzinga
Read moreWill S&P 500 Open Up Or Down On May 1 After Best Month Since 2020?
05/01 04:50 am
Benzinga
Read more3 Healthcare Stocks With the Most Durable Competitive Moats
04/23 04:05 am
The Motley Fool
Read morePress Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
04/18 06:00 am
GlobeNewswire Inc.
Read moreCommuniqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe
04/18 06:00 am
GlobeNewswire Inc.
Read morePRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
04/17 03:00 pm
GlobeNewswire Inc.
Read moreLooks Like M&A Week in 3 Different Sectors
04/08 12:02 pm
The Motley Fool
Read moreOil Tumbles, Nasdaq 100 Jumps 3% As Iran Says It's Ready To Halt Hostilities: 10 Stocks Moving
03/31 02:09 pm
Benzinga
Read moreModerna Stock is Soaring. Is It Too Late to Buy?
03/25 03:10 pm
The Motley Fool
Read morePfizer vs Moderna: Which Pharma Stock Has More Upside?
03/19 03:30 pm
The Motley Fool
Read moreCytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
03/17 10:46 pm
GlobeNewswire Inc.
Read moreISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
03/17 09:35 am
The Motley Fool
Read moreBioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture
03/10 08:40 am
Benzinga
Read more9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential
03/05 03:42 pm
Investing.com
Read moreModerna's $950 Million Settlement Clears Legal Overhang, Stock Soars
03/04 09:14 am
Benzinga
Read moreModerna's Ups and Downs: Here's What You Need to Know Before Investing.
02/25 09:15 am
The Motley Fool
Read moreModerna, Coinbase, And Global Payments Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?
02/22 10:05 am
Benzinga
Read moreBillionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.
02/21 06:10 am
The Motley Fool
Read moreModerna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot
02/20 12:02 pm
Benzinga
Read more3 Once-in-a-Decade Buying Opportunities
02/18 07:10 pm
The Motley Fool
Read moreStock Market Today, Feb. 18: Nvidia Rallies As Meta Deal Boosts AI Confidence
02/18 06:06 pm
The Motley Fool
Read moreFDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars
02/18 02:20 pm
Benzinga
Read moreSofter-Than-Expected Inflation Sparks Rally In These 10 Stocks
02/13 11:01 am
Benzinga
Read more1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell
02/10 02:15 pm
The Motley Fool
Read moreModerna, Mexico Partner To Boost Local Vaccine Production
02/10 01:26 pm
Benzinga
Read moreShould You Buy Moderna Before Feb. 13?
02/10 12:15 am
The Motley Fool
Read moreHuman Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider
02/05 04:57 am
GlobeNewswire Inc.
Read moreTom Gardner's 2026 Outlook: Volatility, Government Scrutiny, and Two AI-Adjacent Stocks
02/04 05:29 pm
The Motley Fool
Read moreCytomX Therapeutics to Present at Upcoming February Conferences
02/04 09:00 am
GlobeNewswire Inc.
Read moreStock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
01/26 06:02 pm
The Motley Fool
Read moreHecla Mining, Moderna, And Micron Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 19-Jan. 23): Are the Others in Your Portfolio?
01/25 10:01 am
Benzinga
Read moreLipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid Therapies
01/23 11:00 am
GlobeNewswire Inc.
Read moreStock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Rise As BEA Pegs Q3 GDP At 4.4%— Microsoft, Moderna, Intel In Focus (UPDATED)
01/22 09:46 am
Benzinga
Read moreModerna Stock Rallies as Oncology Results Improve the Platform’s Value Case
01/21 03:38 pm
Investing.com
Read moreStocks Rebound On Trump's Remarks, Natural Gas Rockets: What's Moving Markets Wednesday?
01/21 02:57 pm
Benzinga
Read moreModerna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
01/21 12:14 pm
Investing.com
Read moreModerna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma
01/20 05:21 pm
Benzinga
Read moreSilver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?
01/13 02:04 pm
Benzinga
Read moreMy Top 5 Stocks to Buy in Early 2026
01/07 05:15 am
The Motley Fool
Read moreSilver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday?
12/26 01:47 pm
Benzinga
Read moreNanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations
12/17 11:00 am
GlobeNewswire Inc.
Read moreXOMA Royalty Enters into Agreement to Acquire Generation Bio
12/15 06:00 pm
GlobeNewswire Inc.
Read moreImmatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
12/11 08:00 am
GlobeNewswire Inc.
Read moreSeasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035
12/03 11:00 am
GlobeNewswire Inc.
Read moreWhere Will Vertex Pharmaceuticals Be in 5 Years
11/27 07:31 am
The Motley Fool
Read moreAI Just Sparked Biotech's Biggest Rally Since 2004 — Why Isn't Anyone Talking About It?
11/25 04:14 pm
Benzinga
Read moreCytomX Therapeutics to Present at the Jefferies London Healthcare Conference
11/13 09:00 am
GlobeNewswire Inc.
Read moreImmatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
11/12 08:00 am
GlobeNewswire Inc.
Read moreCytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
10/30 08:00 am
GlobeNewswire Inc.
Read more